In a significant milestone for its mission to address medication shortages, FindRx has been awarded a $10,000 grant from Northeastern University’s IDEA venture accelerator. This funding marks a new chapter for the innovative healthcare startup, which has been transforming the way patients access critical medications since its launch in May 2024.
FindRx’s platform has already made a meaningful impact by connecting patients with essential therapies, such as ADHD medications and diabetic injections, during times of scarcity. FindRx is creating a streamlined solution to an issue that affects millions.
The $10,000 grant from IDEA, Northeastern’s renowned venture accelerator program, reflects a strong vote of confidence in FindRx’s vision and its potential to revolutionize the pharmaceutical industry. With this funding, the company plans to enhance its platform, scale its operations, and further its mission to ensure that no patient has to struggle to find the medications they need.
“Receiving this grant from IDEA is a tremendous honor and a pivotal moment for FindRx,” said Jay Choi, founder of FindRx and a pharmacy student at Northeastern University. “This support will allow us to accelerate our growth and make an even greater impact on patients who depend on us during some of their most challenging times.”
IDEA’s support is part of its mission to empower young entrepreneurs and innovative startups. Through grants, mentorship, and resources, the accelerator has helped numerous ventures achieve success, and FindRx is proud to join the ranks of its beneficiaries.
As FindRx continues to build on its early success, this funding provides a strong foundation for the company to pursue its broader goals.
The journey ahead for FindRx is ambitious, but with the backing of IDEA and the passion of its dedicated team, the company is poised to make a lasting impact on the healthcare landscape.
For more updates on FindRx and its progress, stay connected as the company continues to drive innovation in the pharmaceutical space.
Jay Choi
Northeastern University, PharmD Candidate
2024/12/15
Comments